New combo attack targets genetic flaw in blood cancers
NCT ID NCT04493164
Summary
This study is testing whether combining two drugs, CPX-351 (a chemotherapy) and ivosidenib (a targeted pill), can help control a specific type of acute myeloid leukemia or high-risk MDS that has an IDH1 gene mutation. It will involve about 30 adults who are eligible for intensive chemotherapy. The main goal is to see how well the combination works to put the disease into remission and to monitor its safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.